Virtue Insight's Biosimilars Congregation 2024

19th Annual Biosimilars Congregation 2024

“Uniting market leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

Virtue Insight is proud to announce that 19th Annual Biosimilars Congregation 2024 happening on 11th December 2024, Hotel Kohinoor Continental, Mumbai, India.

Please contact Email – kavitha@virtueinsight.co.in or Call - +91 44 24762472/ M: +91 9361957193

SPONSORSHIP:

Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries kavitha@virtueinsight.co.in

DELEGATE REGISTRATION:

Super Early Bird Discount Price (Valid till 18th Oct 2024) - INR 11,000 + GST per delegate

Early Bird Discount Price (Valid till 19th Oct 2024 – 22nd Nov 2024) - INR 14,000 + GST per delegate

Standard Price - INR 16,000 + GST per delegate

KEY SPEAKERS:

• SANJEEV GUPTA, Sr. Vice President & Head Biosimilar, Ipca Laboratories

• SD SINHA, Senior VP, Development, Hetero Labs

• ABIR BANERJEE, VP & Head R&D Biotech, Bharat Serums and Vaccines

• SANTOSH TAUR, Director Medical Affairs, Vaccines, Rare Diseases & Digital, Pfizer

• MANNAN KHAMBATI, Assistant VP Biotech Manufacturing, Bharat Serums and Vaccines

• SOURABH FULMALI, Global Medical Director, GSK

• SANCHIT NANDA, Senior Director, Global Patient Solutions, Gilead Sciences

• AMARNATH SUGUMARAN, Associate Director & Cluster Head Medical Affairs, Cipla

• UDAY HARLE, Asst. VP/ Global Head Clinical Development, Kashiv BioSciences

• ABHISHEK SINHA, Global Director - Regulatory Affairs, Advanz Pharma

• AKSHAYA ODAK, Head - Regulatory Affairs (Biotech), Lupin

• MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates

• PRITHWIJIT KUNDU, CMO - NCE, NDD, Wockhardt

• PANKAJ THAKUR, GM, Clinical Project Management - Drug Discovery, Biologics, Hetero Labs

• DATTATRAY PAWAR, Head Medical Affairs - Deputy GM, Alkem Laboratories

• SEEMA BHANDARKAR, Global Program Manager Biosimilar Operations, Biocon

• UMA SINHA DATTA, Director PDS India, Cytiva

• SANJAY B. NIRANJAN, Assistant Director, Bioassay Development (Biosimilars), Lupin

• ANURAG TIWARI, AVP, R&D, Zumutor Biologics

• KAVITA LAMROR, Partner, RWE & Digital Transformation, Maxis Clinical Sciences

• ROSHAN PAWAR, Head Medical Affairs, Alkem Laboratories

• SAMIR KULKARNI, Head - DBT ICT Center, Institute Of Chemical Technology

• SWEETY MATHEW, Regulatory Professional- Global Regulatory Affairs: CMC Rare Diseases, Novo Nordisk

• RANJIT BARSHIKAR, CEO, QBD International, United Nations Adviser

• SHALU KASLIWAL, Group Lead - Medical Sciences, Biologics, Dr. Reddy's Laboratories

• APARNA PRABHUNE, Asst GM Regulatory Affairs, Wockhardt

• KHOKAN DEBNATH, Sr GM/(Head) – Regulatory Affairs, Clinical Operations, PV & QA (India & Emerging Market), Wockhardt

• VISHWAS SOVANI, Founder Director, Pharmawisdom

Plus more joining soon

KEY THEMES DISCUSSED:

• Integrated approach to biosimilar development & commercialization

• Current trends and strategies to access biosimilar market

• Innovative clinical approach in biosimilars & Clinical development of biosimilars

• Factors that drive the selection of a biosimilar asset

• Imperatives for R&D in biosimilars - Entering the next wave of growth

• Addressing developmental challenges to maximize biosimilars market growth

• Global Perspectives: Impact of Biosimilars around the world – What have we learned so far?

• Market Access - Implications for product launch and market exclusivity

• Commitment to Quality - Excellence in manufacturing biosimilars

• Overcoming Barriers to the Market Access of Biosimilars

• Who can influence payers on Biosimilar decision making

• What type of evidence will be needed for registering Biosimilars in the future?

• Outlining what investors wish inventors knew before coming to the table

• RWE - What type of evidence will be needed for registering Biosimilars in the future?

• Ensuring the balance between product development and patient safety

• Technology: Unlocking the better ways

• Regulatory - The evolving regulatory framework for biosimilar approvals

• What comes next for the biosimilars market?

• Be part of a major networking opportunity

WHO SHOULD ATTEND AND WHO YOU’LL MEET:

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins, Biologics/Biotechnology/ Bio generics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory , Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affair